Exploration of the Cell-Cycle Genes Found Within the RIKEN Fantom2data Set Alistair R.R
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Chromosomal Aberrations in Head and Neck Squamous Cell Carcinomas in Norwegian and Sudanese Populations by Array Comparative Genomic Hybridization
825-843 12/9/08 15:31 Page 825 ONCOLOGY REPORTS 20: 825-843, 2008 825 Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization ERIC ROMAN1,2, LEONARDO A. MEZA-ZEPEDA3, STINE H. KRESSE3, OLA MYKLEBOST3,4, ENDRE N. VASSTRAND2 and SALAH O. IBRAHIM1,2 1Department of Biomedicine, Faculty of Medicine and Dentistry, University of Bergen, Jonas Lies vei 91; 2Department of Oral Sciences - Periodontology, Faculty of Medicine and Dentistry, University of Bergen, Årstadveien 17, 5009 Bergen; 3Department of Tumor Biology, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, 0310 Oslo; 4Department of Molecular Biosciences, University of Oslo, Blindernveien 31, 0371 Oslo, Norway Received January 30, 2008; Accepted April 29, 2008 DOI: 10.3892/or_00000080 Abstract. We used microarray-based comparative genomic logical parameters showed little correlation, suggesting an hybridization to explore genome-wide profiles of chromosomal occurrence of gains/losses regardless of ethnic differences and aberrations in 26 samples of head and neck cancers compared clinicopathological status between the patients from the two to their pair-wise normal controls. The samples were obtained countries. Our findings indicate the existence of common from Sudanese (n=11) and Norwegian (n=15) patients. The gene-specific amplifications/deletions in these tumors, findings were correlated with clinicopathological variables. regardless of the source of the samples or attributed We identified the amplification of 41 common chromosomal carcinogenic risk factors. regions (harboring 149 candidate genes) and the deletion of 22 (28 candidate genes). Predominant chromosomal alterations Introduction that were observed included high-level amplification at 1q21 (harboring the S100A gene family) and 11q22 (including Head and neck squamous cell carcinoma (HNSCC), including several MMP family members). -
Genome-Wide Approach to Identify Risk Factors for Therapy-Related Myeloid Leukemia
Leukemia (2006) 20, 239–246 & 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00 www.nature.com/leu ORIGINAL ARTICLE Genome-wide approach to identify risk factors for therapy-related myeloid leukemia A Bogni1, C Cheng2, W Liu2, W Yang1, J Pfeffer1, S Mukatira3, D French1, JR Downing4, C-H Pui4,5,6 and MV Relling1,6 1Department of Pharmaceutical Sciences, The University of Tennessee, Memphis, TN, USA; 2Department of Biostatistics, The University of Tennessee, Memphis, TN, USA; 3Hartwell Center, The University of Tennessee, Memphis, TN, USA; 4Department of Pathology, The University of Tennessee, Memphis, TN, USA; 5Department of Hematology/Oncology St Jude Children’s Research Hospital, The University of Tennessee, Memphis, TN, USA; and 6Colleges of Medicine and Pharmacy, The University of Tennessee, Memphis, TN, USA Using a target gene approach, only a few host genetic risk therapy increases, the importance of identifying host factors for factors for treatment-related myeloid leukemia (t-ML) have been secondary neoplasms increases. defined. Gene expression microarrays allow for a more 4 genome-wide approach to assess possible genetic risk factors Because DNA microarrays interrogate multiple ( 10 000) for t-ML. We assessed gene expression profiles (n ¼ 12 625 genes in one experiment, they allow for a ‘genome-wide’ probe sets) in diagnostic acute lymphoblastic leukemic cells assessment of genes that may predispose to leukemogenesis. from 228 children treated on protocols that included leukemo- DNA microarray analysis of gene expression has been used to genic agents such as etoposide, 13 of whom developed t-ML. identify distinct expression profiles that are characteristic of Expression of 68 probes, corresponding to 63 genes, was different leukemia subtypes.13,14 Studies using this method have significantly related to risk of t-ML. -
Anti-Cdk8 Antibody Produced in Rabbit (C0238)
ANTI-CDK8 Developed in Rabbit, Affinity Isolated Antibody Product Number C 0238 Product Description Reagent Anti-Cyclin-Dependent Kinase 8 (CDK8) is developed in Anti-CDK8, at approximately 1 mg/ml, is supplied as a rabbit using a synthetic peptide corresponding to the solution in phosphate buffered saline, pH 7.4 containing C-terminal region (aa 451-464) of human CDK8. The 0.2% BSA and 15 mM sodium azide. antibody is purified by protein A affinity chromatography. Anti-CDK8 specifically recognizes a 54 kDa protein Precautions and Disclaimer identified as cyclin-dependent kinase 8 (CDK8). Anti- Due to the sodium azide content, a material safety data CDK8 does not crossreact with the other members of sheet (MSDS) for this product has been sent to the CDK family. It detects human, mouse and rat CDK8. It attention of the safety officer of your institution. Consult is used in immunoblotting, immunoprecipitation and the MSDS for information regarding hazardous and safe immunofluorescence applications. handling practices. Cyclin-dependent kinase 8 (CDK8) is a 464-amino acid Storage/Stability protein containing the sequence motifs and 11 Store at –20 °C. For extended storage, upon initial subdomains characteristic of a serine/threonine-specific thawing, freeze the solution in working aliquots. kinase.1 CDKs become activated through binding to Avoid repeated freezing and thawing to prevent cyclins, formation of cyclin-CDK complexes and denaturing the antibody. Storage in “frost-free” reversible phosphorylation reactions. Cyclin-CDK freezers is also not recommended. If slight complexes directly control progression through G1, S, turbidity occurs upon prolonged storage, clarify the G2 and M phases of the cell division cycle. -
Multi-Targeted Mechanisms Underlying the Endothelial Protective Effects of the Diabetic-Safe Sweetener Erythritol
Multi-Targeted Mechanisms Underlying the Endothelial Protective Effects of the Diabetic-Safe Sweetener Erythritol Danie¨lle M. P. H. J. Boesten1*., Alvin Berger2.¤, Peter de Cock3, Hua Dong4, Bruce D. Hammock4, Gertjan J. M. den Hartog1, Aalt Bast1 1 Department of Toxicology, Maastricht University, Maastricht, The Netherlands, 2 Global Food Research, Cargill, Wayzata, Minnesota, United States of America, 3 Cargill RandD Center Europe, Vilvoorde, Belgium, 4 Department of Entomology and UCD Comprehensive Cancer Center, University of California Davis, Davis, California, United States of America Abstract Diabetes is characterized by hyperglycemia and development of vascular pathology. Endothelial cell dysfunction is a starting point for pathogenesis of vascular complications in diabetes. We previously showed the polyol erythritol to be a hydroxyl radical scavenger preventing endothelial cell dysfunction onset in diabetic rats. To unravel mechanisms, other than scavenging of radicals, by which erythritol mediates this protective effect, we evaluated effects of erythritol in endothelial cells exposed to normal (7 mM) and high glucose (30 mM) or diabetic stressors (e.g. SIN-1) using targeted and transcriptomic approaches. This study demonstrates that erythritol (i.e. under non-diabetic conditions) has minimal effects on endothelial cells. However, under hyperglycemic conditions erythritol protected endothelial cells against cell death induced by diabetic stressors (i.e. high glucose and peroxynitrite). Also a number of harmful effects caused by high glucose, e.g. increased nitric oxide release, are reversed. Additionally, total transcriptome analysis indicated that biological processes which are differentially regulated due to high glucose are corrected by erythritol. We conclude that erythritol protects endothelial cells during high glucose conditions via effects on multiple targets. -
Goat Anti-RCBTB2 Antibody Size: 100Μg Specific Antibody in 200Μl
EB09067 - Goat Anti-RCBTB2 Antibody Size: 100µg specific antibody in 200µl Target Protein Principal Names: RCBTB2, regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2, CHC1L, OTTHUMP00000018399, RCC1-like G UK Office exchanging factor RLG, chromosome condensation 1-like, regulator of chromosome condensation and BTB domain containing protein 2 Everest Biotech Ltd Official Symbol: RCBTB2 Cherwell Innovation Centre Accession Number(s): NP_001259.1 77 Heyford Park Human GeneID(s): 1102 Upper Heyford Non-Human GeneID(s): 105670 (mouse), 290363 (rat) Oxfordshire Important Comments: This antibody is not expected to cross-react with RCBTB1. OX25 5HD UK Immunogen Peptide with sequence CEHFRSSLEDNEDD, from the internal region of the protein Enquiries: sequence according to NP_001259.1. [email protected] Sales: Please note the peptide is available for sale. [email protected] Tech support: Purification and Storage [email protected] Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Tel: +44 (0)1869 238326 Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum Fax: +44 (0)1869 238327 albumin. Aliquot and store at -20°C. Minimize freezing and thawing. US Office Everest Biotech c/o Abcore Applications Tested 405 Maple Street, Suite A106 Peptide ELISA: antibody detection limit dilution 1:2000. Ramona, Western blot: Preliminary experiments gave an approx. 30kDa band in Human Liver, CA 92065 Lung and Tonsil lysates after 1µg/ml antibody staining. Please note that currently we USA cannot find an explanation in the literature for the band we observe given the calculated size of 60.3kDa according to NP_001259.1. -
Rangap1 Induces Gtpase Activity of Nuclear Ras-Related Ran (Gtpase-Activating Protein/Rccl/TC4/G2 Checkpoint) F
Proc. Nati. Acad. Sci. USA Vol. 91, pp. 2587-2591, March 1994 Biochemistry RanGAP1 induces GTPase activity of nuclear Ras-related Ran (GTPase-activating protein/RCCl/TC4/G2 checkpoint) F. RALF BISCHOFF*t, CHRISTIAN KLEBEt, JURGEN KRETSCHMER*, ALFRED WITrINGHOFERt, AND HERWIG PONSTINGL* *Division for Molecular Biology of Mitosis, German Cancer Research Center, D-69120 Heidelberg, Federal Republic of Germany; and *Abteilung Strukturelle Biologie, Max-Planck-Institut ffr Molekulare Physiologie, D-44139 Dortmund, Federal Republic of Germany Communicated by Hans Neurath, December 3, 1993 ABSTRACT The nuclear Ras-related protein Ran binds DMAE-650/M (Merck; Superformance, 26 x 115 mm) in 20 guanine nucleotide and is involved in cell cycle regulation. mM Bis-Tris-propane HCl, pH 7.0/1 mM DTT with a linear Models of the signal pathway predict Ran to be active as gradient of NaCl from 0.05 M to 1 M at a flow rate of 5 Ran GTP at the initiation of S phase upon activation by the ml/min. Fractions containing RanGAP were pooled and nucleotide exchange factor RCC1 and to be inactivated for the immediately applied to a hydroxylapatite column (Merck; onset of mitosis by hydrolysis of bound GTP. Here a nuclear Superformance, 10 x 150 mm) in 20 mM potassium phos- homodimeric 65-kDa protein, RanGAPl, is described, which phate, pH 7.0/1 mM DTT, with a linear gradient from 20 mM we believe to be the immediate antagonist of RCC1. It was to 1 M phosphate at a flow rate of 2 ml/min. To fractions purified from HeLa cell lysates and induces GTPase activity of containing RanGAP, ammonium sulfate in 20 mM Bis-Tris- Ran, but not Ras, by more than 3 orders of magnitude. -
Supplemental Information
Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig. -
Dominant Negative Selection of Heterologous Genes
Proc. Nati. Acad. Sci. USA Vol. 89, pp. 9410-9414, October 1992 Genetics Dominant negative selection of heterologous genes: Isolation of Candida albicans genes that interfere with Saccharomyces cerevisiae mating factor-induced cell cycle arrest MALCOLM WHITEWAY*, DANIEL DIGNARD, AND DAVID Y. THOMAS Eukaryotic Genetics Group, National Research Council of Canada, Biotechnology Research Institute, Montr6al, Qu6bec, Canada, H4P 2R2 Communicated by Ira Herskowitz, June 30, 1992 (receivedfor review December 2, 1991) ABSTRACT We have used a genomic library of Candida analysis of the pheromone response pathway. Recessive albicans to transform Saccharomyces cerevisiae and screened mutations leading to pheromone resistance (7, 8) have iden- for genes that act similarly to dominant negative mutations by tified genes encoding the a-pheromone receptor (9, 10), the interfering with pheromone-mediated cell cycle arrest. Six pheromone response G-protein fB subunit (11), two protein different plasmids were identified from 2000 transformants; kinases (12, 13), a transcription factor (14), and a product four have been sequenced. One gene (CZFI) encodes a protein apparently involved in regulating cyclin activity (8). Domi- with structural motifs characteristic of a transcription factor. nant mutations leading to pheromone resistance led to the A second gene (CCNI) encodes a cyclin homologue, a third isolation of a G1 cyclin (15). In addition, overexpression ofS. (CRLI) encodes a protein with sequence similarity to GTP- cerevisiae genes that reduce pheromone sensitivity has al- binding proteins of the RHO family, and a fourth (CEKI) lowed the identification of a G-protein a subunit (16) as well encodes a putative kinase of the ERK family. Since CEKI as the KSS1 protein kinase (17). -
IGH Rearrangement in Myeloid Neoplasms Sion and Activation
CASE REPORTS genes such as MYC and BCL2, leading to their overexpres- IGH rearrangement in myeloid neoplasms sion and activation. Here, we found two IGH rearrange- ments in myeloid tumors, including an IGH-MECOM in a Though immunoglobulin genes are typically expressed myelodysplastic syndrome (MDS) and an IGH-CCNG1 in in B lymphocytes, recent studies found ectopic an AML. Our studies provide the first evidence that a once immunoglobulin expression in non-B-cell tumor cells believed B-cell tumor-specific oncogenic mechanism is including acute myeloid leukemia (AML). The also present in myeloid tumors. immunoglobulin genes, including immunoglobulin heavy Case #1: A 60-year-old female with a history of breast chain genes (IGH), light kappa (k) chain genes (IGK) and cancer presented with fatigue, bilateral flank pain, and 9 light lambda (λ) chain genes (IGL), are frequently hematuria. Complete blood count showed 24.82x10 /L of rearranged in B-cell tumors. These rearrangements result white blood cells, 11.2 g/dL of hemoglobin, 33.9% of in a juxtaposition of IG enhancers to the vicinity of onco- hematocrit, and 68x109/L of platelets. The bone marrow A B C D E Figure 1. Acute myeloid leukemia with an IGH-CCNG1 rearrangement. (A) Chromosome analysis of the bone marrow aspirate showed a complex karyotype, including an unbalanced translocation involving chromosomes 5, 14 and 19. Arrows indicate clonal aberrations. (B) Fluorescence in situ hybridization (FISH) on abnormal metaphase showed the 3'IGH (red) remaining on the derivative chromosome 14 and the 5'IGH lost, consistent with an unbalanced IGH rearrange- ment. -
The Murine Orthologue of the Golgi-Localized TPTE Protein Provides Clues to the Evolutionary History of the Human TPTE Gene Family
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by RERO DOC Digital Library Hum Genet (2001) 109:569–575 DOI 10.1007/s004390100607 ORIGINAL INVESTIGATION Michel Guipponi · Caroline Tapparel · Olivier Jousson · Nathalie Scamuffa · Christophe Mas · Colette Rossier · Pierre Hutter · Paolo Meda · Robert Lyle · Alexandre Reymond · Stylianos E. Antonarakis The murine orthologue of the Golgi-localized TPTE protein provides clues to the evolutionary history of the human TPTE gene family Received: 5 June 2001 / Accepted: 17 August 2001 / Published online: 27 October 2001 © Springer-Verlag 2001 Abstract The human TPTE gene encodes a testis-spe- events. The Y chromosome copy of TPTE is a pseudo- cific protein that contains four potential transmembrane gene and is not therefore involved in the testis expression domains and a protein tyrosine phosphatase motif, and of this gene family. shows homology to the tumor suppressor PTEN/MMAC1. Chromosomal mapping revealed multiple copies of the TPTE gene present on the acrocentric chromosomes 13, Introduction 15, 21 and 22, and the Y chromosome. Zooblot analysis suggests that mice may possess only one copy of TPTE. We have recently identified a testis-specific cDNA, TPTE In the present study, we report the isolation and initial (Transmembrane Phosphatase with TEnsin homology), characterization of the full-length cDNA of the mouse ho- that encodes a predicted protein of 551 amino acids con- mologue Tpte. At least three different mRNA transcripts taining four potential transmembrane domains and a tyro- (Tpte.a, b, c) are produced via alternative splicing, encod- sine phosphatase motif (Chen H et al. -
Regulatory Functions of the Mediator Kinases CDK8 and CDK19 Charli B
TRANSCRIPTION 2019, VOL. 10, NO. 2, 76–90 https://doi.org/10.1080/21541264.2018.1556915 REVIEW Regulatory functions of the Mediator kinases CDK8 and CDK19 Charli B. Fant and Dylan J. Taatjes Department of Biochemistry, University of Colorado, Boulder, CO, USA ABSTRACT ARTICLE HISTORY The Mediator-associated kinases CDK8 and CDK19 function in the context of three additional Received 19 September 2018 proteins: CCNC and MED12, which activate CDK8/CDK19 kinase function, and MED13, which Revised 13 November 2018 enables their association with the Mediator complex. The Mediator kinases affect RNA polymerase Accepted 20 November 2018 II (pol II) transcription indirectly, through phosphorylation of transcription factors and by control- KEYWORDS ling Mediator structure and function. In this review, we discuss cellular roles of the Mediator Mediator kinase; enhancer; kinases and mechanisms that enable their biological functions. We focus on sequence-specific, transcription; RNA DNA-binding transcription factors and other Mediator kinase substrates, and how CDK8 or CDK19 polymerase II; chromatin may enable metabolic and transcriptional reprogramming through enhancers and chromatin looping. We also summarize Mediator kinase inhibitors and their therapeutic potential. Throughout, we note conserved and divergent functions between yeast and mammalian CDK8, and highlight many aspects of kinase module function that remain enigmatic, ranging from potential roles in pol II promoter-proximal pausing to liquid-liquid phase separation. Introduction and MED13L associate in a mutually exclusive fash- ion with MED12 and MED13 [12], and their poten- The CDK8 kinase exists in a 600 kDa complex tial functional distinctions remain unclear. known as the CDK8 module, which consists of four CDK8 is considered both an oncogene [13–15] proteins (CDK8, CCNC, MED12, MED13). -
Dissertation
Regulation of gene silencing: From microRNA biogenesis to post-translational modifications of TNRC6 complexes DISSERTATION zur Erlangung des DOKTORGRADES DER NATURWISSENSCHAFTEN (Dr. rer. nat.) der Fakultät Biologie und Vorklinische Medizin der Universität Regensburg vorgelegt von Johannes Danner aus Eggenfelden im Jahr 2017 Das Promotionsgesuch wurde eingereicht am: 12.09.2017 Die Arbeit wurde angeleitet von: Prof. Dr. Gunter Meister Johannes Danner Summary ‘From microRNA biogenesis to post-translational modifications of TNRC6 complexes’ summarizes the two main projects, beginning with the influence of specific RNA binding proteins on miRNA biogenesis processes. The fate of the mature miRNA is determined by the incorporation into Argonaute proteins followed by a complex formation with TNRC6 proteins as core molecules of gene silencing complexes. miRNAs are transcribed as stem-loop structured primary transcripts (pri-miRNA) by Pol II. The further nuclear processing is carried out by the microprocessor complex containing the RNase III enzyme Drosha, which cleaves the pri-miRNA to precursor-miRNA (pre-miRNA). After Exportin-5 mediated transport of the pre-miRNA to the cytoplasm, the RNase III enzyme Dicer cleaves off the terminal loop resulting in a 21-24 nt long double-stranded RNA. One of the strands is incorporated in the RNA-induced silencing complex (RISC), where it directly interacts with a member of the Argonaute protein family. The miRNA guides the mature RISC complex to partially complementary target sites on mRNAs leading to gene silencing. During this process TNRC6 proteins interact with Argonaute and recruit additional factors to mediate translational repression and target mRNA destabilization through deadenylation and decapping leading to mRNA decay.